NCT04149275撤回2 期
A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Percent progression free survival according to RECIST v1.1
研究概览
简要总结
The purpose of this study is to test the safety of Cabozantinib in combination with Nivolumab and Ipilimumab and see what affects that this combination treatment has on those with recurrent carcinosarcomas.
详细描述
Primary Objectives:
• To estimate the proportion of patients with recurrent carcinosarcoma, who survive progression-free for at least 6 months, treated with cabozantinib + nivolumab + ipilimumab in the second-line and beyond setting (per iRECIST).
Secondary Objectives:
- To evaluate time to progression (Time Frame: From the date the patient received the first study treatment dose until the date of first documented progression, assessed up to 2 years). Progression Free Survival (PFS) according to iRECIST.
- To determine the nature and degree of toxicity of cabozantinib + nivolumab + ipilimumab in this cohort of patients. Toxicity according to CTCAE v4.03
- To estimate the overall survival (OS) of patients with carcinosarcoma treated with cabozantinib + nivolumab + ipilimumab
Exploratory Objectives:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of carcinosarcoma (independent of organ of origin).
- •Received at least one prior chemotherapy regimen for their cancer.
- •Must have measurable or evaluable lesion defined by iRECIST.
- •Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless AE(s) are clinically non-significant and/or stable on supportive therapy.
- •Karnofsky performance status greater than or equal to 70% or ECOG PS = 0~2
- •Age ≥ 18 years.
- •Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:
- •Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 GI/L) without granulocyte colony-stimulating factor support.
- •White blood cell count ≥ 2500/mm3 (≥ 2.5 GI/L).
- •Platelets ≥ 100,000/mm3 (≥ 100 GI/L) without transfusion.
- •Hemoglobin ≥ 9 g/dL (≥ 90 g/L).
- •Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.
- •Total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert's disease ≤ 3 x ULN).
- •Serum albumin ≥ 2.8 g/dl.
- •Serum creatinine ≤ 2.0 x ULN or calculated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation: [(140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)] × 0.85
- •Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol).
- •Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
- •Women of childbearing potential (WOCBP) ie. sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 5 months after the last dose of study treatment.
- •Females should not breastfeed while receiving treatment on trial.
- •Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.
排除标准
- •Prior treatment with cabozantinib.
- •Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.
- •Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.
- •Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
- •Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.
- •Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel). Allowed anticoagulants are the following:
- •Low-dose aspirin for cardioprotection (per local applicable guidelines) is permitted.
- •Low-dose low molecular weight heparins (LMWH) are permitted.
- •Anticoagulation with therapeutic doses of LMWH is allowed in subjects without known brain metastases who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.
- •The subject has prothrombin time (PT)/INR or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 7 days before the first dose of study treatment.
- •The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
- •a. Cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.
- •ii. Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment.
- •iii. Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 6 months before first dose.
- •b. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: i. The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.
- •ii. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.
- •Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose.
- •c. Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose.
- •d. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.
- •e. Lesions invading or encasing any major blood vessels. f. Other clinically significant disorders that would preclude safe study participation.
- •i. Serious non-healing wound/ulcer/bone fracture. ii. Uncompensated/symptomatic hypothyroidism. iii. Moderate to severe hepatic impairment (Child-Pugh B or C).
- •Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before first dose and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before first dose. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
- •Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment [add reference for Fridericia formula].
- •Note: If a single ECG shows a QTcF with an absolute value > 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.
- •Inability to swallow tablets.
- •Previously identified allergy or hypersensitivity to components of the study treatment formulations.
- •Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.
- •Patients with concurrent cytotoxic chemotherapy or radiation therapy are excluded.
- •Patients with a serious chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.
- •Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.
- •Presence of a known active acute or chronic infection including: a urinary tract infection, HIV or viral hepatitis.
研究组 & 干预措施
Cabozantinib + Nivolumab + Ipilimumab
Experimental
All recurrent carcinosarcomas
干预措施: Cabozantinib (Drug)
Cabozantinib + Nivolumab + Ipilimumab
Experimental
All recurrent carcinosarcomas
干预措施: Ipilimumab (Drug)
Cabozantinib + Nivolumab + Ipilimumab
Experimental
All recurrent carcinosarcomas
干预措施: Nivolumab (Drug)
结局指标
主要结局
Percent progression free survival according to RECIST v1.1
时间窗: Baseline through 6 months
To estimate the proportion of patients with recurrent carcinosarcoma, who survive progression-free for at least 6 months, treated with cabozantinib + nivolumab + ipilimumab in the second-line and beyond setting (per iRECIST).
次要结局
- Percent time to progression according to RECIST v1.1(Baseline through 2 years)
- Percent overall survival according to RECIST v1.1(Baseline through 2 years)
- Percent of patients with toxicity according to CTCAE v4.03(Baseline through 2 years)
研究者
Rebecca Arend
Principal Investigator
University of Alabama at Birmingham
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerCastration-resistant Prostate CancerMetastatic CancerNCT05502315Rana McKay, MD47
进行中（未招募）
1 期
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsBladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaBladder Urothelial CarcinomaInvasive Bladder Plasmacytoid Urothelial CarcinomaInvasive Bladder Sarcomatoid Urothelial CarcinomaInvasive Sarcomatoid Urothelial CarcinomaKidney Medullary CarcinomaMalignant Genitourinary System NeoplasmMalignant Solid NeoplasmPenile CarcinomaPenile Squamous Cell CarcinomaRenal Pelvis Urothelial CarcinomaSarcomatoid Renal Cell CarcinomaStage III Bladder Cancer AJCC v8Stage III Penile Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage III Renal Pelvis and Ureter Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage III Urethral Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Penile Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Renal Pelvis and Ureter Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Ureter Urothelial CarcinomaUrethral Urothelial CarcinomaClear Cell Renal Cell CarcinomaRenal Cell CarcinomaNCT02496208National Cancer Institute (NCI)152
进行中（未招募）
2 期
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCPapillary Renal Cell CarcinomaUnclassified Renal Cell CarcinomaTranslocation Renal Cell CarcinomaChromophobe Renal Cell CarcinomaCollecting Duct Renal Cell CarcinomaUnresectable Advanced Renal Cell CarcinomaMetastatic Ncc Renal Cell CarcinomaRenal Cell CarcinomaNCT04413123Bradley A. McGregor, MD60
招募中
2 期
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsBladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed AdenocarcinomaBladder Neuroendocrine CarcinomaBladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaChromophobe Renal Cell CarcinomaCollecting Duct CarcinomaInvasive Bladder Giant Cell Urothelial CarcinomaInvasive Bladder Lymphoepithelioma-Like CarcinomaInvasive Bladder Nested Urothelial CarcinomaInvasive Bladder Plasmacytoid Urothelial CarcinomaInvasive Bladder Sarcomatoid Urothelial CarcinomaInvasive Bladder Urothelial CarcinomaKidney Medullary CarcinomaLarge Cell Neuroendocrine CarcinomaMalignant Testicular Leydig Cell TumorMalignant Testicular Sertoli Cell TumorMetastatic Bladder CarcinomaMetastatic Bladder Clear Cell (Glycogen-Rich) Urothelial CarcinomaMetastatic Bladder Giant Cell Urothelial CarcinomaMetastatic Bladder Large Cell Neuroendocrine CarcinomaMetastatic Bladder Lipid-Rich Urothelial CarcinomaMetastatic Bladder Micropapillary Urothelial CarcinomaMetastatic Bladder Plasmacytoid Urothelial CarcinomaMetastatic Bladder Sarcomatoid Urothelial CarcinomaMetastatic Bladder Small Cell Neuroendocrine CarcinomaMetastatic Bladder Squamous Cell CarcinomaMetastatic Chromophobe Renal Cell CarcinomaMetastatic Kidney Medullary CarcinomaMetastatic Malignant Genitourinary System NeoplasmMetastatic Papillary Renal Cell CarcinomaMetastatic Penile CarcinomaMetastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Sarcomatoid Renal Cell CarcinomaMetastatic Urethral CarcinomaSarcomatoid Renal Cell CarcinomaStage IV Bladder Cancer AJCC v8Stage IV Penile Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Urachal AdenocarcinomaUrethral Clear Cell AdenocarcinomaPapillary Renal Cell CarcinomaNCT03866382National Cancer Institute (NCI)314
进行中（未招募）
1 期
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the BrainMetastatic Renal Cell CarcinomaBrain MetastasesNCT06132945Memorial Sloan Kettering Cancer Center2